Vir Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vir Biotechnology, Inc. on March 4, 2026. The report discloses a corporate governance event regarding the appointment of a senior executive officer.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
On March 4, 2026, the Board of Directors appointed Marianne De Backer, M.Sc., Ph.D., MBA, to the additional position of President. Dr. De Backer currently serves as the Company's Chief Executive Officer and principal executive officer.
Management Commentary and Risks
- Appointment Details: There are no arrangements or understandings between Dr. De Backer and any other person pursuant to which she was named President.
- Relationships: There is no family relationship between Dr. De Backer and any of Vir Bio's directors or executive officers.
- Conflicts of Interest: Dr. De Backer has no direct or indirect interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
- Biographical Data: Detailed biographical information is incorporated by reference from the definitive proxy statement on Schedule 14A filed on April 17, 2025.
Investor Verification Checklist
- Verify the effective date of the President appointment (March 4, 2026).
- Review the Schedule 14A filed on April 17, 2025, for Dr. De Backer's full biographical details.
- Confirm that no undisclosed compensatory arrangements or family relationships exist as stated in the filing.